Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.
Eur J Endocrinol. 2021 Jan;184(1):K7-K10. doi: 10.1530/EJE-20-0634.
The least significant change (LSC) is a term used in individuals in order to evaluate whether one measurement has changed significantly from the previous one. It is widely used when assessing bone mineral density (BMD) scans. To the best of our knowledge, there no such estimate available in the literature for patients with disorders of calcium metabolism. Our aim was to provide an estimate of the least significant change for albumin-adjusted calcium in patients with normocalcaemic hyperparathyroidism (NPHPT) and primary hyperparathyroidism (PHPT).
We used the within-subject standard deviatio calculated in a population of NPHPT and PHPT patients and multiplied it by 2.77.
The LSC for NPHPT and PHPT were found to be 0.25 and 0.24 mmol/L, respectively (1.00 and 0.96 mg/dL). In clinical practice, the value of 0.25 mmol/L could be used.
The least significant change given, could be used in two ways in these patients. First, it gives a range to which values are expected. This can provide some reassurance for the patient and the physician in cases of intermittent hypercalcaemia. Moreover, it can be a marker of whether an individual has an actual significant change of his calcium after parathyroid surgery.
最小有意义变化(LSC)是用于个体的一个术语,用于评估一次测量与前一次测量相比是否有显著变化。当评估骨密度(BMD)扫描时,它被广泛使用。据我们所知,对于钙代谢紊乱的患者,文献中没有这样的估计值。我们的目的是为正常血钙性甲状旁腺功能亢进症(NPHPT)和原发性甲状旁腺功能亢进症(PHPT)患者的白蛋白校正钙提供最小有意义变化的估计值。
我们使用了 NPHPT 和 PHPT 患者人群中的个体内标准差,并将其乘以 2.77。
NPHPT 和 PHPT 的 LSC 分别为 0.25 和 0.24 mmol/L(分别为 1.00 和 0.96 mg/dL)。在临床实践中,可以使用 0.25 mmol/L 的值。
给出的最小有意义变化,可以在这两种患者中以两种方式使用。首先,它给出了预期值的范围。这可以为患者和医生在间歇性高钙血症的情况下提供一些保证。此外,它可以作为甲状旁腺手术后个体钙是否有实际显著变化的标志物。